{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T05:50:59Z","timestamp":1790661059297,"version":"4.1.0"},"reference-count":37,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JPR"],"DOI":"10.2147\/jpr.s541820","type":"journal-article","created":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T20:20:13Z","timestamp":1767817213000},"page":"1-11","source":"Crossref","is-referenced-by-count":1,"title":["Evaluation of Abuse Deterrent Formulations of Oxycodone Products: Real-World Data from an Enriched Population of Substance Users Assessed with the Addiction Severity Index-Multimedia Version (ASI-MV\u00ae)"],"prefix":"10.2147","volume":"Volume 19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1776-6400","authenticated-orcid":true,"given":"Jody","family":"Green","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taryn","family":"Dailey-Govoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Vosburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,1]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Garnett MF, Minino AM. Drug overdose deaths in the United States, 2003\u20132023. NCHS Data Brief. National Center for Health Statistics; 2024:522. doi:10.15620\/cdc\/170565","DOI":"10.15620\/cdc\/170565"},{"key":"ref2","unstructured":"Ahmad FB, Cisewski JA, Rossen LM, Sutton P. Provisional drug overdose death counts. 2025. Available from: https:\/\/www.cdc.gov\/nchs\/nvss\/vsrr\/drug-overdose-data.htm. Accessed October 24, 2025."},{"key":"ref3","doi-asserted-by":"publisher","first-page":"169630","DOI":"10.15620\/cdc\/169630","author":"Lucas","year":"2024","journal-title":"NCHS Data Brief"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1097\/j.pain.0000000000003056","volume":"165","author":"De La Rosa","year":"2024","journal-title":"Pain"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.jpain.2018.07.006","volume":"20","author":"Pitcher","year":"2019","journal-title":"J Pain"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.rr7103a1","volume":"71","author":"Dowell","year":"2022","journal-title":"MMWR Recomm Rep"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.drugalcdep.2017.01.039","volume":"175","author":"Green","year":"2017","journal-title":"Drug Alcohol Depend"},{"key":"ref8","unstructured":"CDER. Abuse deterrent opioids\u2014evaluation and labeling, guidance for industry. Division of Drug Information; 2015. Available from: https:\/\/www.fda.gov\/downloads\/Drugs\/Guidances\/UCM334743.pdf. Accessed October 24, 2025."},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1002\/pds.3522","volume":"22","author":"Coplan","year":"2013","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.jpain.2012.08.008","volume":"14","author":"Butler","year":"2013","journal-title":"J Pain"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.2147\/JPR.S304805","volume":"14","author":"Green","year":"2021","journal-title":"J Pain Res"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"3660","DOI":"10.1093\/pm\/pnaa272","volume":"21","author":"Severtson","year":"2020","journal-title":"Pain Med"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1016\/j.jpain.2013.04.011","volume":"14","author":"Severtson","year":"2013","journal-title":"J Pain"},{"key":"ref14","first-page":"21","volume":"13","author":"Petrilla","year":"2020","journal-title":"Am Health Drug Benefits"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"281","DOI":"10.5055\/jom.0878","volume":"20","author":"Green","year":"2024","journal-title":"J Opioid Manag"},{"key":"ref16","unstructured":"Notice FR. Determination that the OXYCONTIN (Oxycodone Hydrochloride) drug products covered by new drug application 20\u2013553 were withdrawn from sale for reasons of safety or effectiveness. Silver Spring, MD: HHS; 2013:23273\u201323275."},{"key":"ref17","unstructured":"Pharma P. OxyContin medication prescribing information and label. 2023. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/022272s048lbl.pdf. Accessed October 24, 2025."},{"key":"ref18","unstructured":"Pharmaceutical C. XTAMPZA ER medication prescribing information and label. 2023. Available from: https:\/\/www.xtampzaer.com\/assets\/pdf\/xtampza-pi.pdf. Accessed December 20, 2025."},{"key":"ref19","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s40261-023-01259-6","volume":"43","author":"Jewell","year":"2023","journal-title":"Clin Drug Investig"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s40261-023-01248-9","volume":"43","author":"Jewell","year":"2023","journal-title":"Clin Drug Investig"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"119","DOI":"10.2147\/CEOR.S340290","volume":"14","author":"Olatoke","year":"2022","journal-title":"Clinicoecon Outcomes Res"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"519","DOI":"10.2217\/pmt-2022-0068","volume":"13","author":"Severtson","year":"2023","journal-title":"Pain Manag"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1037\/0893-164x.15.1.4","volume":"15","author":"Butler","year":"2001","journal-title":"Psychol Addict Behav"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/0740-5472(89)90041-x","volume":"6","author":"Hendriks","year":"1989","journal-title":"J Subst Abuse Treat"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1097\/00005053-198310000-00003","volume":"171","author":"Kosten","year":"1983","journal-title":"J Nerv Ment Dis"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/0740-5472(92)90062-s","volume":"9","author":"McLellan","year":"1992","journal-title":"J Subst Abuse Treat"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"8","DOI":"10.4097\/kjae.2016.69.1.8","volume":"69","author":"Nahm","year":"2016","journal-title":"Korean J Anesthesiol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.1213\/ANE.0000000000005101","volume":"131","author":"Schober","year":"2020","journal-title":"Anesth Analg"},{"key":"ref29","volume-title":"Nonparametric Statistics for the Behavioral Sciences","year":"1988"},{"key":"ref30","unstructured":"Boehm R. Primer on disproportionality analysis. Open Vigil Source Forge; 2018."},{"key":"ref31","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1093\/jamia\/ocv063","volume":"23","author":"Duggirala","year":"2016","journal-title":"J Am Med Inform Assoc"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"461","DOI":"10.2217\/pmt-2017-0030","volume":"7","author":"Brennan","year":"2017","journal-title":"Pain Manag"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"57","DOI":"10.5055\/jom.2016.0312","volume":"12","author":"Fleming","year":"2016","journal-title":"J Opioid Manag"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s40122-016-0062-1","volume":"5","author":"Gudin","year":"2016","journal-title":"Pain Ther"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"127","DOI":"10.5055\/jom.2020.0559","volume":"16","author":"Gudin","year":"2020","journal-title":"J Opioid Manag"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1007\/s40261-017-0599-8","volume":"37","author":"Mayock","year":"2017","journal-title":"Clin Drug Investig"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1007\/s40261-017-0561-9","volume":"37","author":"Mayock","year":"2017","journal-title":"Clin Drug Investig"}],"container-title":["Journal of Pain Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/article\/download\/110764","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.dovepress.com\/article\/download\/110764","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T20:20:15Z","timestamp":1767817215000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dovepress.com\/evaluation-of-abuse-deterrent-formulations-of-oxycodone-products-real--peer-reviewed-fulltext-article-JPR"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":37,"URL":"https:\/\/doi.org\/10.2147\/jpr.s541820","relation":{},"ISSN":["1178-7090"],"issn-type":[{"value":"1178-7090","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]}}}